Lantheus (NASDAQ:LNTH) Stock Price Down 5.5% – Here’s What Happened

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s share price traded down 5.5% during mid-day trading on Tuesday . The company traded as low as $92.55 and last traded at $92.90. 141,442 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 673,070 shares. The stock had previously closed at $98.31.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial reissued a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Trading Down 9.1 %

The firm has a market capitalization of $6.21 billion, a PE ratio of 14.87 and a beta of 0.46. The stock has a 50 day simple moving average of $91.55 and a 200 day simple moving average of $100.35.

Insider Activity

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its holdings in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares in the last quarter. Moloney Securities Asset Management LLC purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $1,066,000. Massachusetts Financial Services Co. MA purchased a new position in shares of Lantheus in the 3rd quarter valued at approximately $25,955,000. Van ECK Associates Corp lifted its position in Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after acquiring an additional 21,604 shares during the period. Finally, Empirical Asset Management LLC bought a new stake in Lantheus during the fourth quarter worth about $323,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.